AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37039805 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration (n=286) (Control)
Number of subjects: 574
Study 37039805 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 574
Study 37039805 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration (Control)
Number of subjects: 574
Study 37039790 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (n=231)
Number of subjects: 679
Study 37039790 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB (n=217)
Number of subjects: 679
Study 37039790 — intervention group
Group type: COMPARATOR
Intervention: Control (n=231)
Number of subjects: 679
Study 37039948 — intervention group
Group type: EXPERIMENTAL
Intervention: faricimab 6 mg up to every 16 weeks (Q16W) after 4 initial Q4W doses
Number of subjects: 133
Study 37039948 — intervention group
Group type: COMPARATOR
Intervention: aflibercept 2 mg Q8W after 3 initial Q4W doses
Number of subjects: 133
Study 37039948 — intervention group
Group type: EXPERIMENTAL
Intervention: faricimab
Number of subjects: 133
Study 37039948 — intervention group
Group type: COMPARATOR
Intervention: aflibercept
Number of subjects: 133
Study 37039967 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g twice daily, starting from 5 days preoperatively until 10 days postoperatively)
Number of subjects: 253
Study 37039967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 37039967 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g twice daily)
Number of subjects: 253
Study 37039975 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence-imaging
Number of subjects: 350
Study 37039975 — intervention group
Group type: COMPARATOR
Intervention: Clinical signs and symptoms of infection (CSS)
Number of subjects: 350
Study 37039975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to detect TBL >10
Number of subjects: 350
Study 37040046 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8353/selumetinib 100/50 mg
Number of subjects: 30
Study 37040046 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8353/selumetinib 150/75 mg
Number of subjects: 30
Study 37040046 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8353/selumetinib (all doses)
Number of subjects: 30
Study 37040046 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-8353/selumetinib 50/25 mg and 100/50 mg
Number of subjects: 30
Study 37040086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent HPV 16/18 vaccine
Number of subjects: 3727
Study 37040116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecanemab 10 mg/kg biweekly
Number of subjects: 854
Study 37040116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecanemab 10 mg/kg monthly
Number of subjects: 854
Study 37040116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 854
Study 37040167 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby (HMHB) intervention group
Number of subjects: 120
Study 37040167 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) control group
Number of subjects: 120
Study 37040172 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature selection methods and classification approaches (support vector machine, logistic regression, decision trees, random forest, extra-trees)
Number of subjects: 56
Study 37040172 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic data inclusion in classification approaches
Number of subjects: 56
Study 37040172 — intervention group
Group type: EXPERIMENTAL
Intervention: DESeq2 as a feature selection method and extra-trees classifier
Number of subjects: 56
Study 37040172 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of 5 genes (CDIPT, MRC2, PATL2, RFXANK, SUMO3)
Number of subjects: 56
Study 37040304 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious Illness Conversation Training for Interprofessional Primary Care Teams
Number of subjects: 0
Study 37040386 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with cancer
Number of subjects: 213
Study 37040386 — intervention group
Group type: COMPARATOR
Intervention: Individuals without cancer
Number of subjects: 213
Study 37040388 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-altering variants in cytotoxicity genes in IRIS patients (n = 56)
Number of subjects: 82
Study 37040388 — intervention group
Group type: COMPARATOR
Intervention: Protein-altering variants in cytotoxicity genes in non-IRIS patients (n = 26)
Number of subjects: 82
Study 37040544 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 46
Study 37040544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 37040553 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (CADx)
Number of subjects: 320
Study 37040553 — intervention group
Group type: COMPARATOR
Intervention: Endoscopist predictions
Number of subjects: 320
Study 37040553 — intervention group
Group type: EXPERIMENTAL
Intervention: CADx
Number of subjects: 320
Study 37040553 — intervention group
Group type: EXPERIMENTAL
Intervention: CADx and endoscopist predictions
Number of subjects: 320
Study 37040726 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 291
Study 37040839 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 476
Study 37040839 — intervention group
Group type: COMPARATOR
Intervention: Electronic medical record portal messaging
Number of subjects: 476
Study 37040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 0 (11.6%)
Number of subjects: 1178
Study 37040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 1 (19.5%)
Number of subjects: 1178
Study 37040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 2 to 3 (29.4%)
Number of subjects: 1178
Study 37040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 4 to 5 (31.5%)
Number of subjects: 1178
Study 37040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe postoperative disability (mRS 4 to 5)
Number of subjects: 1178
Study 37040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate postoperative disability (mRS 2 to 3)
Number of subjects: 1178
Study 37040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 0
Number of subjects: 1178
Study 37040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 1
Number of subjects: 1178
Study 37040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 2 to 3
Number of subjects: 1178
Study 37040850 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stroke-related disability classified as mRS 4 to 5
Number of subjects: 1178
Study 37040861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Coronary Roadmap (DCR) guidance during PCI
Number of subjects: 394
Study 37040861 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI without DCR guidance
Number of subjects: 394
Study 37041046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine mouthwash (4 times daily for 2 weeks)
Number of subjects: 23
Study 37041046 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine mouthwash
Number of subjects: 23
Study 37041057 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunonutritional supplement (INS) for 6 months
Number of subjects: 696
Study 37041057 — intervention group
Group type: COMPARATOR
Intervention: Normal diet for 6 months
Number of subjects: 696
Study 37041057 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunonutritional supplement (INS)
Number of subjects: 696
Study 37041063 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP POCT intervention
Number of subjects: 0
Study 37041081 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute encephalopathy in patients with severe COVID-19
Number of subjects: 374
Study 37041081 — intervention group
Group type: EXPERIMENTAL
Intervention: Age older than 70 years
Number of subjects: 374
Study 37041081 — intervention group
Group type: EXPERIMENTAL
Intervention: Presumed fatal comorbidity
Number of subjects: 374
Study 37041081 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow coma scale score <9 before/at ICU admission
Number of subjects: 374
Study 37041081 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressor/inotrope support during ICU stay
Number of subjects: 374
Study 37041081 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy during ICU stay
Number of subjects: 374
Study 37041081 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS ischemic or hemorrhagic complications as acute encephalopathy etiology
Number of subjects: 374
Study 37041081 — intervention group
Group type: EXPERIMENTAL
Intervention: Status epilepticus, posterior reversible encephalopathy syndrome, and reversible cerebral vasoconstriction syndrome
Number of subjects: 374
Study 37041205 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Cycloserine (100 mg) with repeated spaced iTBS
Number of subjects: 20
Study 37041205 — intervention group
Group type: COMPARATOR
Intervention: Placebo with repeated spaced iTBS
Number of subjects: 20
Study 37041472 — intervention group
Group type: EXPERIMENTAL
Intervention: BPI-9016M 300 mg QD
Number of subjects: 38
Study 37041472 — intervention group
Group type: EXPERIMENTAL
Intervention: BPI-9016M 450 mg QD
Number of subjects: 38
Study 37041472 — intervention group
Group type: EXPERIMENTAL
Intervention: BPI-9016M 600 mg QD
Number of subjects: 38
Study 37041472 — intervention group
Group type: EXPERIMENTAL
Intervention: BPI-9016M 400 mg BID (Part B)
Number of subjects: 38
Study 37041539 — intervention group
Group type: EXPERIMENTAL
Intervention: Filapixant 80 mg
Number of subjects: 23
Study 37041539 — intervention group
Group type: EXPERIMENTAL
Intervention: Filapixant 250 mg
Number of subjects: 23
Study 37041539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 37041561 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP titration
Number of subjects: 0
Study 37041561 — intervention group
Group type: COMPARATOR
Intervention: Low fraction of inspired oxygen (FiO2)
Number of subjects: 0
Study 37041600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-to-family telehealth
Number of subjects: 6
Study 37041600 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6
Study 37041669 — intervention group
Group type: EXPERIMENTAL
Intervention: BI + peer
Number of subjects: 739
Study 37041669 — intervention group
Group type: EXPERIMENTAL
Intervention: BI + web
Number of subjects: 739
Study 37041669 — intervention group
Group type: COMPARATOR
Intervention: EUC
Number of subjects: 739
Study 37041704 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 97
Study 37041967 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Number of subjects: 1859
Study 37041967 — intervention group
Group type: COMPARATOR
Intervention: Other SARS-CoV-2 directed treatment
Number of subjects: 1859
Study 37042037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dabrafenib (150 mg twice daily), trametinib (2 mg once daily), and AT13387 (260 mg/m)
Number of subjects: 22
Study 37042037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dabrafenib, trametinib, and AT13387
Number of subjects: 22
Study 37042110 — intervention group
Group type: EXPERIMENTAL
Intervention: Layperson-delivered telephone program focusing on empathy
Number of subjects: 58
Study 37042110 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 58
Study 37042129 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR inhibitors (Infigratinib, futibatinib, pemigatinib)
Number of subjects: 0
Study 37042129 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR inhibitors
Number of subjects: 0
Study 37042129 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine/cisplatin
Number of subjects: 0
Study 37042205 — intervention group
Group type: EXPERIMENTAL
Intervention: BYON3521
Number of subjects: 0
Study 37042284 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Number of subjects: 0
Study 37042284 — intervention group
Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 0
Study 37042284 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of all-cause mortality, nonfatal myocardial infarction, stroke, acute coronary syndrome, or BARC bleeding type ≥3
Number of subjects: 0
Study 37042284 — intervention group
Group type: EXPERIMENTAL
Intervention: BARC bleeding types 2 to 5
Number of subjects: 0
Study 37042306 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital self-control intervention
Number of subjects: 0
Study 37042306 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study 37042316 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted biopsy (VAB)
Number of subjects: 1470
Study 37042316 — intervention group
Group type: COMPARATOR
Intervention: Core needle biopsy (CNB)
Number of subjects: 1470
Study 37042345 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette
Number of subjects: 22
Study 37042345 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated Tobacco Product (HTP)
Number of subjects: 22
Study 37042345 — intervention group
Group type: COMPARATOR
Intervention: Usual Brand Combustible Cigarette (UBC)
Number of subjects: 22
Study 37042345 — intervention group
Group type: COMPARATOR
Intervention: E-cigarette and HTP vs UBC
Number of subjects: 22
Study 37042345 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette vs HTP
Number of subjects: 22
Study 37042545 — intervention group
Group type: COMPARATOR
Intervention: 10 mg rizatriptan
Number of subjects: 133
Study 37042545 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg zolmitriptan
Number of subjects: 133
Study 37042545 — intervention group
Group type: COMPARATOR
Intervention: Triptans (combined data from both studies)
Number of subjects: 133
Study 37042653 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning Serum Cortisol
Number of subjects: 0
Study 37042724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (ADjuVANt Chemotherapy in the Elderly trial)
Number of subjects: 40
Study 37042865 — intervention group
Group type: EXPERIMENTAL
Intervention: Momelotinib
Number of subjects: 725
Study 37042921 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab levels ≤0.32 μg/mL
Number of subjects: 33
Study 37042921 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab levels >0.32 μg/mL
Number of subjects: 33
Study 37042921 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 0 alemtuzumab levels >0.32 μg/mL
Number of subjects: 33
Study 37042921 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL9 levels ≤2394 pg/mL (day 14+ median)
Number of subjects: 33
Study 37042921 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL9 levels >2394 pg/mL (day 14+)
Number of subjects: 33
Study 37043021 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted cochlear implant surgery (RACIS)
Number of subjects: 23
Study 37043021 — intervention group
Group type: COMPARATOR
Intervention: Conventional cochlear implantation
Number of subjects: 23
Study 37043192 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 5438
Study 37043192 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5438
Study 37043197 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol box (SplashGuard CG)
Number of subjects: 122
Study 37043197 — intervention group
Group type: COMPARATOR
Intervention: Control (no aerosol box)
Number of subjects: 122
Study 37043201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural tissue plasminogen activator plus deoxyribonuclease therapy
Number of subjects: 26
Study 37043201 — intervention group
Group type: COMPARATOR
Intervention: Surgical decortication
Number of subjects: 26
Study 37043203 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned Open-label Placebo (C-OLP) with methadone
Number of subjects: 131
Study 37043203 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) with methadone
Number of subjects: 131
Study 37043210 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone (recurrence score <11)
Number of subjects: 9369
Study 37043210 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy alone vs chemotherapy followed by endocrine therapy (recurrence score 11-25)
Number of subjects: 9369
Study 37043210 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by endocrine therapy (recurrence score >25)
Number of subjects: 9369
Study 37043210 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian race
Number of subjects: 9369
Study 37043210 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 9369
Study 37043210 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional recurrence (LRR)
Number of subjects: 9369
Study 37043216 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app-assisted follow-up
Number of subjects: 72
Study 37043216 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-person follow-up
Number of subjects: 72
Study 37043227 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 552
Study 37043227 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 552
Study 37043227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study 37043227 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 552
Study 37043263 — intervention group
Group type: EXPERIMENTAL
Intervention: My Mobile Wallet intervention (real-time adherence monitors, SMS reminders, and mobile money incentives)
Number of subjects: 30
Study 37043263 — intervention group
Group type: EXPERIMENTAL
Intervention: My Mobile Wallet intervention
Number of subjects: 30
Study 37043271 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention (parent-targeted, focused on 6 weight-related behaviors)
Number of subjects: 119
Study 37043271 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention (log-in duration for PA session)
Number of subjects: 119
Study 37043271 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention (log-in duration for sedentary behavior session)
Number of subjects: 119
Study 37043271 — intervention group
Group type: COMPARATOR
Intervention: Web-based health education comparison program
Number of subjects: 119
Study 37043339 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atropine weekly for 6 months
Number of subjects: 207
Study 37043339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine daily for 6 months (phase 2)
Number of subjects: 207
Study 37043339 — intervention group
Group type: COMPARATOR
Intervention: 0.01% atropine daily for 1 year (group B)
Number of subjects: 207
Study 37043339 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atropine
Number of subjects: 207
Study 37043339 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atropine (phase 1)
Number of subjects: 207
Study 37043339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine (phase 2)
Number of subjects: 207
Study 37043339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Number of subjects: 207
Study 37043386 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline high-sensitivity troponin T (hsTnT) ≥14 ng/L
Number of subjects: 732
Study 37043386 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-predictor model including age, sex, eGFR <45 mL·min -1 ·1.73 m -2, functional capacity <4 METs or unknown, NT-proBNP ≥300 pg/mL, and estimated intraoperative blood loss
Number of subjects: 732
Study 37043404 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 70
Study 37043404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 37043520 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mmol KCl intravenous injection
Number of subjects: 81
Study 37043518 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital combined pituitary hormone deficiency (cCPHD) diagnosed before age 18 years
Number of subjects: 128
Study 37043518 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital combined pituitary hormone deficiency (cCPHD) diagnosed <1 year
Number of subjects: 128
Study 37043518 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital combined pituitary hormone deficiency (cCPHD) diagnosed 1-17 years
Number of subjects: 128
Study 37043518 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital combined pituitary hormone deficiency (cCPHD)
Number of subjects: 128
Study 37043555 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37043653 — intervention group
Group type: EXPERIMENTAL
Intervention: Dersimelagon 100 mg once daily for 16 weeks
Number of subjects: 102
Study 37043653 — intervention group
Group type: EXPERIMENTAL
Intervention: Dersimelagon 300 mg once daily for 16 weeks
Number of subjects: 102
Study 37043653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 37043652 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 11000
Study 37043652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11000
Study 37043654 — intervention group
Group type: COMPARATOR
Intervention: Male donor group
Number of subjects: 8719
Study 37043654 — intervention group
Group type: EXPERIMENTAL
Intervention: Female donor group
Number of subjects: 8719
Study 37043729 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Pap test
Number of subjects: 266
Study 37043729 — intervention group
Group type: COMPARATOR
Intervention: Traditional Pap test
Number of subjects: 266
Study 37044158 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDS users
Number of subjects: 395
Study 37044158 — intervention group
Group type: COMPARATOR
Intervention: Cigarette users
Number of subjects: 395
Study 37044281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NaCl (2 grams 3 times a day)
Number of subjects: 65
Study 37044281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 37044281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral NaCl
Number of subjects: 65